TY - JOUR T1 - Selective Wnt/β-catenin Small-molecule Inhibitor CWP232228 Impairs Tumor Growth of Colon Cancer JF - Anticancer Research JO - Anticancer Res SP - 3661 LP - 3667 DO - 10.21873/anticanres.13514 VL - 39 IS - 7 AU - JIN YOUNG KIM AU - GEUMI PARK AU - MANIGANDAN KRISHNAN AU - EUNYOUNG HA AU - KYUNG-SOO CHUN Y1 - 2019/07/01 UR - http://ar.iiarjournals.org/content/39/7/3661.abstract N2 - Background/Aim: To explore the possibility of a selective small-molecule β-catenin inhibitor, CWP232228, as a potential therapeutic drug in the treatment of colorectal cancer (CRC). Materials and Methods: The effect of CWP2228 on HCT116 cells was analysed in vitro via flow cytometry, western immunoblotting, and luciferase reporter assays. NOD-scid IL2Rgammanull mice were employed for an in vivo xenograft study to validate the in vitro studies. Results: CWP232228 treatment decreased the promoter activity and nuclear expression of β-catenin and induced a significant cytotoxic effect in HCT116 cells. CWP232228 treatment induced apoptosis and cell-cycle arrest in the G1 phase of the cell cycle. Furthermore, CWP232228 decreased the expression of aurora kinase A, c-Myc, cyclin D1 and microphthalmia-associated transcription factor. Lastly, CWP232228 also inhibited the growth of xenografted colon cancer cells in mice. Conclusion: Collectively, CWP232228 may be used as a potential therapeutic drug in CRC. ER -